Al-Dawaa Medical Services Company Stock

Equities

4163

SA15H14I11H6

Drug Retailers

Market Closed - Saudi Arabian S.E. 07:58:19 2024-06-13 am EDT 5-day change 1st Jan Change
87.7 SAR -0.34% Intraday chart for Al-Dawaa Medical Services Company +1.50% -17.11%
Sales 2024 * 6.21B 1.65B Sales 2025 * 6.6B 1.76B Capitalization 7.48B 1.99B
Net income 2024 * 400M 107M Net income 2025 * 471M 126M EV / Sales 2024 * 1.44 x
Net Debt 2024 * 1.47B 393M Net Debt 2025 * 1.47B 392M EV / Sales 2025 * 1.36 x
P/E ratio 2024 *
18.8 x
P/E ratio 2025 *
15.9 x
Employees -
Yield 2024 *
3.28%
Yield 2025 *
3.7%
Free-Float 34.2%
More Fundamentals * Assessed data
Dynamic Chart
Aldawaa, Mouwasat Form New Limited Liability Company in Medical Clinics MT
Al Dawaa Medical Services Company Announces the Establishment of Limited Liability Company in Partnership with Mouwasat Medical Services Company CI
Aldawaa Medical Services Posts Higher Q1 Net Profit, Revenue MT
Al-Dawaa Medical Services Company Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Al-Dawaa Medical Services Company Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Al-Dawaa Medical Services Company Announces the Distribution of Cash Dividends for the Second Half of the Year 2023, Payable on February 25, 2024 CI
Al-Dawaa Medical Services Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Al-Dawaa Medical Services Company Reports Earnings Results for the Second Quarter Ended June 30, 2023 CI
Al-Dawaa Medical Services Company Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Al-Dawaa Medical Services Company Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Al-Dawaa Medical Services Company Reports Earnings Results for the Third Quarter Ended September 30, 2022 CI
Al-Dawaa Medical Services Company(SASE:4163) added to S&P Global BMI Index CI
Al-Dawaa Medical Services Company(SASE:4163) added to S&P Pan Arab Composite CI
Certain Ordinary Shares of Al-Dawaa Medical Services Company are subject to a Lock-Up Agreement Ending on 7-SEP-2022. CI
Al-Dawaa Medical Services Company Announces Interim Cash Dividend for the First Half of 2022, Payable on September 20, 2022 CI
More news
1 day-0.34%
1 week+1.50%
Current month-2.45%
1 month-4.47%
3 months-19.39%
6 months-14.85%
Current year-17.11%
More quotes
1 week
86.00
Extreme 86
91.20
1 month
84.80
Extreme 84.8
92.50
Current year
84.80
Extreme 84.8
121.60
1 year
84.80
Extreme 84.8
121.60
3 years
63.00
Extreme 63
121.60
5 years
63.00
Extreme 63
121.60
10 years
63.00
Extreme 63
121.60
More quotes
Managers TitleAgeSince
Chief Executive Officer - 21-06-05
Director/Board Member - 21-06-05
Members of the board TitleAgeSince
Director/Board Member - 21-06-05
Director/Board Member - 21-06-05
Director/Board Member - 21-06-05
More insiders
Date Price Change Volume
24-06-13 88 0.00% 192,128
24-06-12 88 -2.55% 122,345
24-06-11 90.3 +0.33% 240,178
24-06-10 90 +1.47% 569,288
24-06-09 88.7 +2.66% 95,946

Delayed Quote Saudi Arabian S.E., June 13, 2024 at 07:58 am EDT

More quotes
Al Dawaa Medical Services Company SJSC is a Saudi Arabia- based entity, which is primarily engaged in selling pharmaceutical and healthcare products. The Company is engaged in online wholesale of pharmaceutical products, wholesale of pharmaceutical goods, related pharmacy activities, pharmaceutical warehousing activities, and retail of medical equipment, among others. The Company operates in two segments: Retail, which includes the sale of goods to customers commonly at the store checkout for the sales via the Group's pharmacies; and Wholesale, which includes sale of goods to the wholesale customers. The Company’s products include mum and baby, beauty care, personal care, health and wellness, medicine and treatments, and vitamins and healthy nutrition. The Company operates approximately four subsidiaries.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
88 SAR
Average target price
113.3 SAR
Spread / Average Target
+28.79%
Consensus

Quarterly revenue - Rate of surprise